Last reviewed · How we verify
NCT05745597
Prognostic Study of HPV Virus Integration in Women With HSIL
trial testing Follow up in HPV Infection in 1,000 participants. Status unknown.
30 September 2025
Quick facts
| Lead sponsor | Fujian Maternity and Child Health Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 1 January 2023 |
| Primary completion | 30 September 2025 |
| Estimated completion | 31 October 2025 |
| Sites | 13 locations across China |
Drugs / interventions tested
- Follow up
Conditions studied
- HPV Infection — all drugs for HPV Infection →
- Virus Integration — all drugs for Virus Integration →
- HSIL, High Grade Squamous Intraepithelial Lesions — all drugs for HSIL, High Grade Squamous Intraepithelial Lesions →
Sponsor
Fujian Maternity and Child Health Hospital
Who can join
Eligibility, female only, with HPV Infection or Virus Integration. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Human papillomavirus (HPV) is currently one of the most common sexually transmitted infections, according to its carcinogenicity is divided into high-risk genotypes and low-risk genotypes, research has confirmed that carcinogenic HPV type continuous infection leads to a higher incidence of condyloma acuminatum and cervical cancer, while increasing the oropharyngeal cancer, vaginal cancer and other related cancer risk. Based on clinical practice, the purpose of this study was to: 1) identify the correlation between HPV integration and the outcome of disease in HSIL women. 2) To determine the prognostic value of different HPV gene integration status in HSIL women. 3) To clarify the relationship between different HPV gene integration status and diversity of vaginal flora in HSIL women.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05745597
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Follow up
Trials testing the same drug.
- NCT06779344 — MxA and CRP-Guided Use of Antimicrobial Agents for AECOPD · NA · not yet recruiting
- NCT06137352 — Two Domestic HPV Vaccines and Imported HPV Vaccines in Women Aged 13-14 Years Study on Immunogenicity · not yet recruiting
- NCT05282095 — Effect of HPV Integration on Prognosis of Young Women With CIN2 in China · recruiting
- NCT05123417 — Knowledge and Practices of Preventing Pressure Ulcers · NA · completed
- NCT05283239 — Research About Impact of HPV Integration on the Prognosis of Women With Persistent HR-HPV Infection · unknown
Other recruiting trials for HPV Infection
Currently open trials in the same condition.
- NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
- NCT07281677 — Immunogenicity and Safety of Sequential 2vHPV-9vHPV Vaccination in Girls Aged 9-14 Years · Phase 4 · recruiting
- NCT06507917 — Concordance and Acceptability of Self-screening Versus Screening by a Healthcare Professional for HPV, a Risk Factor for · NA · recruiting
- NCT07336134 — PopSci CHW4CervixHealth · NA · recruiting
- NCT06959563 — Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating HPV · EARLY_PHASE1 · active not recruiting
Other Fujian Maternity and Child Health Hospital trials
Trials by the same sponsor.
- NCT06276309 — Protein Molecular Characteristics and Prognosis of Cervical Neuroendocrine Tumors · recruiting
- NCT06137352 — Two Domestic HPV Vaccines and Imported HPV Vaccines in Women Aged 13-14 Years Study on Immunogenicity · not yet recruiting
- NCT06204133 — Model Study on Cervical Cancer Screening Strategies and Risk Prediction · completed
- NCT05932563 — Study on the Epidemiological Characteristics of Female HPV Vaccination in China · unknown
- NCT05932576 — A Multicenter Cohort Study Assessing the Efficacy and Adverse Effects of HPV Vaccination in Chinese Women · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05745597 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fujian Maternity and Child Health Hospital
- Last refreshed: 27 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05745597.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing